Search for a trial

Lambert-Eaton myasthenic syndrome: Clinical characteristics, pathogenesis and tumour association

- To study the clinical characteristics and disease course of patients with LEMS with or without SCLC- To identify the characteristics of the humoral or cellular immune response that are associated with the prolonged survival of patients with SCLC…

DW-MRI in mediastinal restaging after concomitant chemoradiotherapy and prognosis of trimodality treatment for stage IIIA/B NSCLC with mediastinal lymph node metastases and without supraclavicular lymph node metastases ; NSCLC Stadium IIIA/B N2/3

This study aims to investigate the feasability to use DW-MRI for mediastinal restaging after concomitant chemoradiotherapy and the feasabilitiy to predict whether or not mediastinal downstaging will be achieved during concomitant chemoradiotherapy…

Needle based CLE in thoracic lymph nodes, a comparison with pathology.

To identify and define characteristics of healthy lymph nodes and lymph nodes involved in different pulmonal diseases (lungcancer and sarcoidosis)

A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL)

This study will evaluate the long-term safety and efficacy of atezolizumab in patients with locally advanced or metastatic NSCLC who have progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy…

Phase I clinical study combining L19-IL2 with stereotactic ablative body radiotherapy in patients with oligometastatic solid tumor

To determine the safety and tolerability of L19-IL2 combined with SABR.

Optimizing (breathing) techniques for radiotherapy of esophageal and lung carcinomas; a pilot study.

Primary objective: To determine the optimal breathing technique to minimize the dose to the heart of radiotherapy for esophageal and lung cancer using current photon techniques, without compromising the dose to the lungs. Secondary Objectives: 1. To…

CT-controlled advanced navigation techniques for transbronchial pulmonary lesion access; evaluation of augmented fluoroscopy bronchoscopic navigation based diagnostic yield.

Diagnostic yield and navigation accuracy of a combination of commercially available endobronchial navigation and imaging techniques will be evaluated in patients with peripheral pulmonary lesions. Cost-effectiveness and safety will be modelled on…

CT-controlled advanced navigation techniques for transbronchial pulmonary lesion access; evaluation of electromagnetic navigation based diagnostic yield.

Diagnostic yield and navigation accuracy of a combination of commercially available endobronchial navigation and imaging techniques will be evaluated in patients with peripheral pulmonary lesions. Cost-effectiveness and safety will be modelled on…

MRI for radiotherapy treatment planning of stage III NSCLC: an MRI optimization study in healthy volunteers and patients

Healthy volunteers* To select the appropriate techniques to image lung and mediastinal parenchyma. Furthermore, MRI settings will be sought which can be used for motion compensation.Patients* To optimize and validate MRI for the visualization and…

A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (CLDK378A2120C)

Primary: 1. To determine the MTD and/or RDE of the combination ceritinib and nivolumab. 2. To assess the preliminary antitumor activity of the combination.Secondary: 1: To assess the safety profile of the ceritinib and nivolumab combination. 2: To…

Phase II study with oral fibroblast growth factor-1 inhibitor BIBF1120 as treatment in lung carcinoma patients harboring fibroblast growth factor receptor-1 gene amplification (NVALT-15 study)

Primary: To assess PFS of lung cancer patients with an FGFR1 gene amplified in their tumor cells upon treatment with BIBF1120.Secondary: To assess response rate, duration of response, overall survival and safety.

A phase II multicenter, single-arm study of MPDL3280A in patients with PD-L1 positive locally advanced or metastatic non small cell lunch cancer

The primary efficacy objective for this study is to evaluate the efficacy of MPDL3280Ain patients with PD-L1*positive locally advanced or metastatic NSCLC, as measuredby investigator-assessed ORR according to modified RECIST.SECONDARY OBJECTIVESThe…

A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer (CEGF816X2201C)

Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…

Complete endosonographic intrathoracic nodal staging of lung cancer patients in whom SABR is considered.

Complete endosonographic (combined endobronchial and esophageal) staging of hilar and mediastinal lymph nodes in patients with (suspected) non-small cell lung cancer (NSCLC) will result in change of loco-regional nodal status in 20% of patients, in…

A phase II trial evaluating the safety and efficacy of the addition of concurrent anti-PD-1 nivolumab to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B Non-Small Cell Lung Carcinoma

Primary objective: To assess the feasibility of the addition of nivolumab consolidation to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC, as defined by the rate of grade *3 pneumonitis (CTCAE V4.0) 6 months…

A prospective double-blind randomized Phase III study of 300 mg vs. 150 mg erlotinib in current smokers with locally advanced or metastatic NSCLC in second-line setting after failure on chemotherapy

To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.

Validation of simplified quantitative methods for 3*deoxy-3*-[18F]fluorothymidine Positron Emission Tomography ([18F]FLT PET) in patients with non-small cell lung cancer treated with tyrosine kinase inhibitor (gefitinib of erlotinib).

Primary objective: association between pharmacokinetic modeling of [18F]FLT PET and simplified measures during treatment with gefitinib in patients with NSCLC to validate the use of simplified measures during treatment with gefitinib of…

Illness Perceptions in patients with lung cancer

The aim of this research is to gain a more detailed insight into the illness perceptions of patients with lung cancer. With this insight it is our aim to improve biopsychosocial care for these patients. Research question: What are the illness…

A phase Ib open label clinical trial of continuous once daily oral treatment usin BIBW 2992 plus cetuximab (Erbitux) in patients with non-small cell lung cancer (NSCLC) with progression following prior erlotinib (Tarceva) or gefitinib (Iressa)

The primary aim of this study is to determine the Maximum Tolerated Dose (MTD) of BIBW2992 treatment in combination with cetuximab in patients with Non-Small Cell Lung Cancer with acquired resistance to erlotinib or gefitinib.Safety,…

Evaluation of radiation induced pulmonary hypertension using MRI in stage III NSCLC patients treated with chemoradiotherapy. A Pilot Study.

The objective is to test the hypothesis that radiotherapy for lung cancer induces an increase in pulmonary artery pressure.